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Background: The eyes and skin are obvious retinoid target organs. Vitamin A deficiency causes night blindness and
retinoids are widely used to treat acne and psoriasis. However, more than 90% of total body retinol is stored in liver
stellate cells. In addition, hepatocytes produce the largest amount of retinol binding protein and cellular retinoic
acid binding protein to mobilize retinol from the hepatic storage pool and deliver retinol to its receptors,
respectively. Furthermore, hepatocytes express the highest amount of retinoid x receptor alpha (RXRα) among all
the cell types. Surprisingly, the function of endogenous retinoids in the liver has received very little attention.
Results: Based on the data generated from chromatin immunoprecipitation followed by sequencing, the global
DNA binding of transcription factors including retinoid x receptor α (RXRα) along with its partners i.e. retinoic acid
receptor α (RARα), pregnane x receptor (PXR), liver x receptor (LXR), farnesoid x receptor (FXR), and peroxisome
proliferator-activated receptor α (PPARα) has been established. Based on the binding, functional annotation
illustrated the role of those receptors in regulating hepatic lipid homeostasis. To correlate the DNA binding data
with gene expression data, the expression patterns of 576 genes that regulate lipid homeostasis were studied in
wild type and liver RXRα-null mice treated with and without RA. The data showed that RA treatment and
RXRα-deficiency had opposite effects in regulating lipid homeostasis. A subset of genes (114), which could clearly
differentiate the effect of ligand treatment and receptor deficiency, were selected for further functional analysis. The
expression data suggested that RA treatment could produce unsaturated fatty acids and induce triglyceride
breakdown, bile acid secretion, lipolysis, and retinoids elimination. In contrast, RXRα deficiency might induce the
synthesis of saturated fatty acids, triglyceride, cholesterol, bile acids, and retinoids. In addition, DNA binding data
indicated extensive cross-talk among RARα, PXR, LXR, FXR, and PPARα in regulating those RA/RXRα-dependent
gene expression levels. Moreover, RA reduced serum cholesterol, triglyceride, and bile acid levels in mice.
Conclusions: We have characterized the role of hepatic RA for the first time. Hepatic RA mediated through RXRα
and its partners regulates lipid homeostasis.
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The eyes and skin are obvious retinoid target organs. Vita-
min A deficiency causes night blindness and retinoids are
widely used to treat acne and psoriasis. However, more than
90% of total body retinol (retinylpalmitate, the storage form)
is stored in liver stellate cells [1]. In addition, hepatocytes
produce the largest amount of retinol binding protein and
cellular retinoic acid binding protein to mobilize retinol
from the hepatic storage pool and deliver retinol to its re-
ceptors, respectively [2]. Furthermore, hepatocytes express
the highest amount of retinoid x receptor alpha (RXRα)
among all the cell types. Surprisingly, the function of en-
dogenous retinoids in the liver has received very little atten-
tion. Thus, the current study aims to identify the bona fide
RXRα and RARα targets in the liver.
The broad and complicated roles of retinoids can be
explained by the presence of multiple receptors for retin-
oic acid (RA), the biological active form of retinol. The re-
ceptors for RA are retinoic acid receptor (RAR) as well as
retinoid x receptor (RXR) [2]. In addition, RXR is essential
for many other receptors to function. These receptors for
RA belong to a nuclear receptor family whose members
are transcriptional factors. Thus, RA exerts its biological
effects by regulating gene expression. RXR is unique in
that it not only forms homodimers, but also dimerizes
with other nuclear receptors, which include receptors for
fatty acids (peroxisomal proliferator-activated receptors,
PPARs), bile acids (farnesoid x receptor, FXR), oxysterols
(liver x receptor, LXR), xenobiotics (pregnane x receptor,
PXR, and constitutive androstane receptor, CAR), vitamin
D (vitamin D receptor, VDR), and RA (RAR). Hence, most
RXR partners participate in regulating lipid homeostasis.
Within these heterodimers, RXR can be either a permis-
sive or a silent partner. When RXR serves as a silent part-
ner, the heterodimer does not respond to RA. When it is a
permissive (active) partner, RA and the ligand for the
heterodimeric partner can both activate the heterodimer.
For example, RXR is a permissive partner for PPAR [3].
Similarly, heterodimeric complexes of RXR with LXR [4]
or FXR [5] also retain RA responsiveness. Furthermore,
retinoids also activate PXR, VDR, and CAR thus are able
to thus regulate xenobiotic metabolism and potentially
their own oxidation [6-8]. Since most of these receptors
are abundantly expressed in the liver, the endogenous RA
may regulate many hepatic nuclear receptor-mediated
pathways. Therefore, the role of RA in the liver is unpre-
dictable. In order to understand the endogenous function
of RA and its receptors, it is crucial to identify RA recep-
tor targets (genes and pathways) genome-wide.
RXRα is highly expressed in the liver [9]. Liver specific
RXRα-deficient mice have increased serum triglyceride and
cholesterol levels [10,11]. In addition, lack of hepatic RXRα
increases sensitivity to alcohol- and non-alcohol-induced
steatosis and steatohepatitis [12,13]. Besides regulatinglipid metabolism, hepatocyte RXRα also controls xeno-
biotic [14-16], carbohydrate [17], and amino acid metabol-
ism [17]. These findings indicate that RXRα-mediated
signaling has a huge impact on maintaining liver health
and in regulating many disease processes.
To understand the global roles of RXRα and RARα at
the genomic level, chromatin immunoprecipitation using
anti-RXRα and -RARα antibodies followed by sequencing
(ChIP-seq) was performed. Since RXRα is an essential part-
ner for other nuclear receptors, we compared ChIP-seq
data to RXRα binding locations with locations from previ-
ous studies for PXR [18], LXR [19], FXR [20], and PPARα
[19]. Meanwhile, the expression levels of the genes respon-
sible for lipid homeostasis were studied in wild type and
hepatic RXRα-deficient mouse livers. Both genome-wide
DNA-binding and hepatic gene expression data were used
to define the role of RA in the liver. Our data uncovered
the unknown function of retinoic acid and RXR vs. RAR in
the liver. Using different approaches, we showed for the
first time that retinoic acid-activated RXRα and RARα have
distinct effects. Moreover, the action of retinoic acid in the
liver is to regulate lipid homeostasis specifically by redu-
cing serum cholesterol, triglyceride and bile acid levels.
The data provided may lead to future development of syn-
thetic retinoid that can target metabolic syndrome or other
types of lipid-associated health issues.
Results
Genome-wide binding of RXRα, RARα, PXR, LXR, FXR, and
PPARα in mouse livers
To understand the global roles of RXRα and RARα at
the hepatic genome level, ChIP-seq was performed using
anti-RXRα and -RARα antibodies. Single read sequen-
cing yielded 18 and 32 million uniquely mapped reads
for RXRα and RARα, respectively. After filtering by in-
cluding peak scores that were greater than 20 and dis-
tance within 10 kb from the transcriptional start site,
17,973 peaks were detected for RXRα and 18,697 peaks
for RARα. Since RXRα is an essential partner for other
nuclear receptors, we compared ChIP-seq data of RXRα
with those of PXR [18], LXR [19], FXR [20], and PPARα
[19]. Our data showed that the numbers of peaks, which
were commonly bound by RXRα and other nuclear re-
ceptors, were 6,577 for RARα, followed by 5,154 for
PPARα, 2,846 for FXR, 1,190 for LXR, and 868 for PXR
in the mouse liver genome. RARα had less than 50%
overlapping bindings with RXRα while PPARα, FXR,
LXR, and PXR had over 85% overlapping bindings with
RXRα (Figure 1A). These findings suggest that RXRα is
indispensable for the function of PPARα, FXR, LXR and
PXR in the mouse liver. In contrast, RARα may work in
the absence of RXRα. More than 4000 of RARα binding
genes were bound by RXRα, and occupied 56% of total
RXRα bindings, followed by PPARα (43%), FXR (25%),
Figure 1 Histograms showing genome-wide binding of RXRα/nuclear receptor in wild type mouse livers. (A) The overlapping binding
between indicated nuclear receptor (NR) and RXRα. (B) The preferential dimerization of RXRα with nuclear receptors. The number and percentage
of genes bound by RXRα and indicated nuclear receptors are shown in black. The binding occurs in the same location within a gene. I: the
number and percentage of overlapping binding between RXRα and any one of the indicated nuclear receptors. II: the number and percentage of
overlapping binding between RXRα and any one of PXR, LXR, FXR, and PPARα.
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including PPARα, FXR, LXR, and PXR bound to almost
50% of RXRα-bound regions suggesting the extensive role
of RXRα in regulating lipids.
Cluster and principal component analysis (PCA) were
performed using the binding data. Overlapping bindings be-
tween RXRα and RARα, PPARα, FXR, LXR, and PXR were
analyzed. According to the length of the vertical branches
(Figure 2A), LXR and PXR were clustered into one basicFigure 2 Genome-wide profiling of RXRα/nuclear receptor binding sit
nuclear receptor (NR) binding sites. Each horizontal line represents a bindin
the vertical lines represent the distance between the sets of target genes f
analysis for RXRα/nuclear receptors binding sites. Scores of component 1 a
receptors binding sites.group. FXR was clustered into a subgroup with LXR
and PXR. PPARα, PXR, LXR, and FXR were classified
into another group. However, RARα was distant from
the others. The same datasets were subjected to PCA
analysis. After dimension deduction, two components
were picked to describe the global properties of the
samples. The two-dimension score plot showed that
LXR and PXR had the shortest distance, implying their
properties on the genome-wide binding level were mostes. (A) A dendogram was generated by cluster analysis to show RXRα/
g site. White regions indicate there is no peak called. The lengths of
or the nuclear receptors when clustered. (B) A score plot of PCA
nd 2 were obtained from the linear combination of all the nuclear
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PXR was shorter than the distances between other recep-
tors and LXR/PXR. RARα was far from all other nuclear
receptors. Thus, the information generated from the PCA
and cluster analysis was consistent. The difference among
the binding profiles of PXR, LXR, FXR, and PPARα were
described by component 2 while the difference between
the binding profile of RARα and those four nuclear recep-
tors were described by component 1 in the PCA.
Function analysis of the genes that have overlapping
binding sites between RXRα and each of RARα, PXR, LXR,
FXR, and PPARα
To understand the potential biological role of genes likely
to be targeted by RXRα-heterodimers, DAVID functional
annotation was performed. The top ten processes for each
of the heterodimers formed by RXRα and other nuclearTable 1 Common and unique biological function of genes bou
Pathways RARα
Acylglycerol metabolic process
Neutral lipid metabolic process
Glycerol ether metabolic process
Organic ether metabolic process
Carboxylic acid catabolic process 6.1E-11
Organic acid catabolic process 6.1E-11
Coenzyme metabolic process 9.4E-13
Cofactor metabolic process 1.6E-17
Fatty acid metabolic process
Oxidation reduction 1.7E-23
Sterol homeostasis
Cholesterol homeostasis
Lipid homeostasis
Lipid transport
Hexose metabolic process
Steroid metabolic process
Monosaccharide metabolic process
Pyruvate metabolic process
Acute-phase response
Cellular carbohydrate biosynthetic process
Acute inflammatory response
Glucose metabolic process
Response to wounding
Electron transport chain 2.7E-10
ncRNA metabolic process 4.2E-15
mRNA processing 6.7E-16
Translation 7E-16
RNA processing 8.8E-16
Numbers in the table represent the p value given by DAVID.receptors were investigated in this study (Table 1). Al-
though common pathways among these heterodimers, such
as carboxylic acid catabolic process, organic acid catabolic
process, and oxidation reduction, appeared in the top 10
pathways, the heterodimers still have their unique biological
functions. RXRα-RARα uniquely regulated protein trans-
port, localization, and RNA processing. The heterodimers
of RXRα and PXR, LXR, FXR, and PPARα have a great im-
pact on various lipid processing pathways. For example,
RXRα-PPARα and RXRα-LXR tend to bind to the genes in-
volved in acylglycerol, glycerol ether, and neutral lipid meta-
bolic processes, which are fatty acid derived. In addition,
RXRα-PPARα distinctly binds to the genes that are in-
volved in fatty acid metabolic processes, and RXRα-LXR is
more prone to bind to the genes that participate in steroid
metabolic process. In addition to steroid metabolic process,
RXRα-FXR also tends to bind to genes that dictate lipidnd by RXRα coupled with RARα, PXR, LXR, FXR and PPARα
PXR LXR FXR PPARα
1.9E-07 3.8E-10
2.7E-07 9.4E-10
2.7E-07 1E-10
4.5E-11
7.3E-07 2.8E-08 1.9E-09 6.1E-11
7.3E-07 2.8E-08 1.9E-09 6.1E-11
2E-07 1.7E-10
3.0E-06 2.1E-07 2E-11
1.8E-12
1E-11 1.4E-16 6.1E-14 3.4E-28
7.2E-08
7.2E-08
4.8E-07
2E-07
2.1E-07
2.6E-11 2E-08
1.4E-07
1.3E-05
3.2E-05
5.9E-06
7.3E-07
0.00001
3.5E-07
1.8E-09
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stasis. RXRα-PXR targets specific biological processes like
regulating pyruvate and carbohydrate biotransformation,
but it also has a role in acute-phase response, acute inflam-
matory response, and response to wounding. Taken to-
gether, RXRα-RARα targeted protein and RNA processes
while RXRα-PXR/LXR/FXR/PPARα targeted homeostasis
regulation of small molecules, which include monosacchar-
ide and lipids.
Global profiling of the expression of lipid homeostasis
genes in wild type and RXRα KO mice treated with and
without RA
Hepatic RXRα KO mice have elevated serum cholesterol
and triglyceride levels [21], and the majority of PXR, LXR,
FXR, PPARα-bound genes were also bound by RXRα. We
next tested a hypothesis that RA and hepatic RXRα could
regulate lipid homeostasis in the mouse liver via RXRα
and its heterodimeric partners. The expression levels of
the lipid homeostasis genes (579) in the KEGG pathway
database were studied in wild type and hepatic RXRα KO
mice treated with and without RA. The PCA score plot
showed that RA treatment of wild type mice caused a
downward shift in C2 from the untreated control group
(Figure 3A). In contrast, an upward shift was found due to
hepatic RXRα deficiency in comparison to the untreated
wild type mice. Thus, RA treatment and RXRα deficiency
had opposite effects. In addition, no significant change
was noted when RA was used to treat hepatic RXRα KO
mice. These findings unequivocally prove that the effectsFigure 3 PCA of the expression level of 579 lipid genes in wild type a
and hepatic RXRα KO mice were treated with and without RA for 7 days (1
homeostasis was studied. (A) Score plot of PCA showing the difference am
Arrows represent the direction separating groups from the wild type (WT)
observed across all groups. (B) A histogram that shows the loading value o
higher mRNA levels in RXRα KO than wild type livers. In contrast, genes wi
RA treatment.of RA on regulating those lipid homeostasis genes were
RXRα dependent. Score plot (Figure 3A) indicates compo-
nent 2 made a contribution to distinguish groups of con-
trol, RA-treated, and RXRα-deficient mice. Thus, 114 out
of 579 genes with high loading values (>0.5 or < -0.5) in
component 2 were selected for further analysis (Figure 3B).
Among them, 55 genes were induced by RA and had de-
creased expression levels due to RXRα deficiency. The
other 59 genes, whose expression levels were suppressed
by RA, had increased expression levels due to a lack of
RXRα. Thus, the expression levels of those 114 lipid-
related genes are ligand (RA)-responsive and receptor
(RXRα)-dependent. Based on the known function of those
genes described in KEGG and PubMed, the role of those
114 genes was assigned and summarized in Table 2. Re-
markably, RA regulated many genes involved in certain
pathways. For example, RA decreased the expression of 10
genes in the cholesterol biosynthesis pathway, but did not
increase the expression of any other genes in the same
pathway. Thus, it is very likely that RA inhibited the bio-
synthesis of cholesterol in an RXRα-dependent manner.
RA also induced the expression of 13 genes in the RA
elimination process and yet did not reduce the expression
of any gene in the same process. Thus, RA can self-
regulate its own level. Furthermore, RA also induced the
expression of 9 genes in the biosynthesis of unsaturated
fatty acids responsible for anti-inflammation. Since there
was no inhibition of gene expression in the same pathway,
it is very likely that RA up-regulates the synthesis of unsat-
urated fatty acids and has an anti-inflammatory role.nd hepatic RXRα-KO mice treated with and without RA. Wild type
50 mg/kg diet, n = 3). The expression of 579 genes involved lipid
ong the groups. Spots within an ellipse belong to the same group.
mice (open square □). There is no significance in the C1component
f genes on C2. Genes with high loading value (≥ 0.5) on C2 had
th low loading value (≤ -0.5) on C2 had increased mRNA levels due to
Table 2 Biological functions responding to RA treatment
and RXRα knockout in wild type mice
Gene number
(with RXRα bindings)
Biological functions RA induced
& RXRα KO
repressed
RA repressed
& RXRα KO
induced
Lipid droplet growth 1 (0) 2 (2)
Transportation of bile aicds for bile
excretion
1 (0) 0
Dehydrogenation of saturated fatty acids
to unsaturated fatty acids
3 (2) 0
Biosynthesis of glycerol phosphalipids 4 (3) 1 (1)
Tryglyceride degration 4 (3) 0
Biosynthesis of unsaturated fatty acids
responsible for aniti-inflammation
9 (7) 0
Elimination of retinoic acids 13 (11) 0
Biosynthesis of bile acids 4 (4) 4 (4)
Biosynthesis of retinoic acids 1 (1) 2 (2)
Biosynthesis of saturated fatty acids 5 (5) 10 (10)
Degradation of glycerol phosphalipids 1 (1) 4 (4)
Degradation of saturated fatty acids 10 (10) 5 (5)
Elimination of steroid hormones 3 (3) 5 (5)
Fat digestion and absorption 3 (3) 7 (7)
Lipid droplet breakdown
(fat mobilization)
1 (1) 1 (1)
Recycle of bile acids via hepatic-intestine 1 (1) 3 (3)
S1P degradation 1 (1) 1 (1)
Transportation of bile aicds for kidney
excretion
2 (2) 3 (3)
DHS1P degradation 1 (1) 0
Elimination of unsaturated fatty acids
(PGE2) responsible for lipolysis inhibition
1 (1) 0
phosphatidylcholine to
phosphatidylethanolamine
1 (1) 0
Sphingolipid biosynthesis 1 (1) 0
SPH (SM) degradation 0 1 (0)
Biosynthesis of cholesterol 0 10 (10)
Biosynthesis of steroid hormone 0 1 (1)
Biosynthesis of tryglycerides 0 1 (1)
Biosynthesis of unsaturated fatty acids
responsible for pro-inflammation
0 1 (1)
Breakdown of phosphalipid to form
unsaturated fatty acids
0 1 (1)
Elimination of cholesterol (from
cyculation back to liver for catabolism)
0 1 (1)
Elimination of cholesterol via steoid
hormone pathway
0 1 (1)
Phosphatidylethanolamine to
phosphatidylcholine
0 1 (1)
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114) had RXRα binding implying direct gene regulation.
Taken together, ligand (RA) treatment and hepatic
RXRα deficiency resulted in opposite effects. Figure 4
summarizes the effect of RA and hepatic RXRα deficiency
on lipid homeostasis. RXRα deficiency tends to favor satu-
rated fatty acids, triglyceride, cholesterol, and bile acids
synthesis. In contrast, RA treatment leads to unsaturated
fatty acids and phospholipid synthesis and lipolysis as well
as triglyceride breakdown.
Binding of RA/RXRα responsive genes by other nuclear
receptors
Additional analysis was done to understand which other
nuclear receptors may be involved in regulating the ex-
pression of these 114 RA/RXRα target genes, which have
a role in lipid homeostasis. The binding data generated in
the current study (RXRα and RARα) were compared with
the binding data of PXR, LXR, FXR, and PPARα. Figure 5
shows overlapping genes with RXRα-heterodimers, as
assessed by overlapping binding of RXRα and other nu-
clear receptors. The data were organized by the number of
different nuclear receptors binding the genes. For example,
motifs located in the Abca1, Abhd5, Acsl, and Aldh3a2
genes could be bound by RXRα and all five nuclear recep-
tors. Peaks located in the Apoa4, Cyp51, Cyp7b1, and Elovl1
could be bound by RXRα and any 4 out of the 5 studied nu-
clear receptors (Figure 5). Some of the commonly regulated
genes have nuclear receptor binding site at the same loca-
tion. The data indicated extensive crosstalk among nuclear
receptors in regulating the expression of those genes.
Quantification of serum cholesterol, triglyceride, and bile
acid levels
ChIP-Seq and RNA expression profiling indicate the role
of RA in controlling lipid homeostasis in the liver. Serum
cholesterol, triglyceride, and bile acid levels were quanti-
fied to test the genetic findings. The data showed that RA
reduced serum cholesterol, triglyceride as well as bile acid
levels in wild type mice (Figure 6). However, such effects
were not found in hepatic RXRα KO mice. In addition,
serum cholesterol and triglyceride, but not bile acid, levels
were elevated due to RXRα deficiency. These biochemical
findings confirm the role of RA in regulating lipid homeo-
stasis in the liver.
Discussion
This study establishes the role of nuclear receptors and RA
in regulating lipid homeostasis in the liver. In addition, the
mechanisms by which nuclear receptors and RA regulate
lipid homeostasis were illustrated at the gene, pathway, and
systemic levels. Furthermore, relationships between RXRα
and PXR, LXR, FXR, as well as PPARα in regulating lipid
homeostasis were analyzed. These nuclear receptors depend
Figure 4 Lipid synthesis and metabolism pathways regulated by RA treatment and RXRα deficiency. The diagram represents the effect of
RA treatment and RXRα deficiency on the expression of 114 lipid genes based on PCA analysis. Fifty-five genes were induced by RA and inhibited
due to the lack of RXRα, and fifty-nine of them were induced because of RXRα deficiency and RA suppressing. Gene functions were obtained
from the KEGG database and confirmed in PubMed gene database. The arrows inside the circle represent the lipid synthesis processes, and the
outer arrows represent the lipid elimination processes. The “T” sign represents inhibition and all arrows represent inductions.
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their bound genes overlap with those bound by RXRα. The
nuclear receptor binding data were strengthened by profil-
ing the expression patterns of 576 lipid genes, which
showed that RA treatment and RXRα-deficiency had an op-
posite effect in regulating lipid homeostasis. Nuclear recep-
tor binding data also illustrated extensive cross talk among
the studied nuclear receptors. Thus, our novel in vivo data
provided extensive evidence showing the role of RA in dic-
tating lipid homeostasis in the liver.
It is intriguing that more than 85% of the PXR, LXR,
FXR, and PPARα binding sites overlapped with those of
RXRα. In contrast, only 43% of RARα binding sites over-
lapped with those of RXRα. It has been shown that RARα
can form homodimers [22]. It is also possible that RARα
may dimerize with RXRβ and RXRγ to exert its function.
Although the percentage of overlapping bindings between
RARα and RXRα is not as high as others, the number of
genes that could be bound by RXRα/RARα (4554) is the
highest, followed by RXRα/PPARα (3468), RXRα/FXR
(2019), RXRα/LXR (988), and RXRα/PXR (666), implying
the relatively extensive role of these nuclear receptors in
regulating hepatic gene expression. It is important to fur-
ther study the role of RARα and other RARs in the liver. By
forming partners with other nuclear receptors, RXRα is a
master regulator. Our data showed that more than 8000
hepatic genes were bound by RXRα, and 72% of them over-
lapped with the genes bound by RARα, PXR, LXR, FXR, or
PPARα. The remaining 28% of RXRα binding sites might
be bound by RXRα homodimer or the heterodimer ofRXRα and VDR or CAR. Thus, the five nuclear receptors
(RARα, PXR, LXR, FXR, or PPARα) analyzed in the current
study account for almost three quarters of RXRα binding
genes in the liver. Furthermore, nearly 50% of RXRα bind-
ings overlapped with the bindings of PXR, LXR, FXR, and
PPARα (Figure 1B). Hence, lipid regulation should be one
of the major functions of RXRα.
Clustering and PCA showed that the genome-wide
binding pattern of RARα is not similar to that of PPARα,
LXR, PXR, and FXR. Biological function annotation also
showed that RARα has some unique features including
protein processing, protein localization, and RNA process-
ing. However, the five studied nuclear receptors also dem-
onstrated functional redundancy. For example, there are
four pathways, including oxidation reduction, carboxylic
acid catabolic process, organic acid catabolic process, and
cofactor metabolic process, that can be regulated by more
than four nuclear receptors. This finding suggests the im-
portance of these four pathways in the liver, and the role
of RARα in them.
Although PPARα, LXR, FXR, and PXR have extensive
roles in regulating lipids, they also have specific roles in
regulating different types of lipids. RXRα/PPARα prefers to
bind to genes that participate in neutral lipids, glycerol
ether, and organic ether as well as fatty acid metabolism
processes. All of which are either fatty acid-derived prod-
ucts or precursors for the biosynthesis of fatty acids. An-
other pathway bound by RXRα/PPARα is the acylglycerol
metabolic process, which is involved in triglyceride homeo-
stasis. RXRα/LXR tends to regulate genes involved in sterol
Figure 5 Heat maps showing the binding profiles of RXRα/nuclear receptor on 96 RA-responsive and RXRα-dependent lipid genes. RA
responsive and RXRα-dependent genes (114) were analyzed by nuclear receptor binding. Among those 114 genes, 96 genes shown in black lines
can be commonly regulated by RXRα and its partner. Some of the commonly regulated genes have nuclear receptor binding site at the
same location.
Figure 6 Serum cholesterol, triglyceride, and bile acid levels in wild type and hepatocyte RXRα KO mice treated with and without RA.
Male wild type (WT) and hepatocyte RXRα KO (KO) mice were fed laboratory chow with (black bars) and without (white bars) all-trans RA
(150 mg/kg diet) for 7 days (n = 6). Serum cholesterol (A), triglyceride (B), and bile acid (C) levels were quantified at the end of the treatment.
* p < 0.01.
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RXRα/FXR not only binds to the genes participating in
steroid metabolism process, but also those involved in lipid
transport and carbohydrate metabolism processes. RXRα/
PXR binds to the genes involved in regulating the pyruvate
metabolic process at the DNA binding level. Pyruvate is a
key intersection for fatty acid, carbohydrate, and protein
metabolisms. In addition, RXRα/PXR also regulates re-
sponse to acute phase, inflammatory, and wounding, im-
plying that PXR can be an excellent target for metabolism
and inflammation-related health issues. Lastly, FXR binds
to the genes involved in monosaccharide metabolism,
which shows the intimate relationship between bile acid
and glucose homeostasis [24].
All of the 114 genes that showed differential effects
of RA treatment and RXRα deficiency are bounded
by RXRα and RARα, PXR, LXR, FXR, and PPARα
heterodimers. These findings indicate that those stud-
ied nuclear receptors retain RA response in vivo and
the effect of RA is dependent upon those nuclear re-
ceptors. RA has a broad spectrum of effects including
biosynthesis of retinoids, phospholipids, and unsatur-
ated fatty acids. It also has a role in eliminating reti-
noids, oxidizing saturated fatty acids, and breaking
down triglycerides. It seems that RA has extensive
beneficial effects in maintaining the health of the liver.
Specifically, RA induced the expression of Cyp2c37/
38/50/54/70 and Cyp2j5. These genes encode enzymes
involved in the generation of epoxyeicosatrienoic acids
[25], which have anti-inflammatory effects [26]. In
contrast, RXRα deficiency induces the gene expression
of Cyp4f that is responsible for the generation of 20-
hydroxyeicosatetraenoic acid, a pro-inflammation mol-
ecule [25]. In addition, RA increases mRNA levels of
cbr1(carbonyl reductase 1), which is responsible for
transforming prostaglandin E2 to prostaglandin F2α.
Prostaglandin E2 and F2α have different effects in
regulating lipid breakdown. Prostaglandin E2 is a lip-
olysis inhibitor [27]; whereas, prostaglandin F2α has
not been shown to have the same effect. Thus, the in-
duction of cbr1 gene expression could be a mechanism
by which RA induces lipolysis. RA also induces expres-
sion levels of gene encoding proteins for phospholipid
biosynthesis, but RXRα deficiency increases the expres-
sion of the genes that have a role in the degradation of
phospholipids. This finding suggests the potential role
of RA in maintaining the normal structure of the cell
membrane. Formation of the monolayer of lipoprotein
or lipid droplet is one of the major ways that phospho-
lipids regulate lipid metabolism [28]. Phosphatidyletha-
nolamine (PE) and phosphatidylcholine (PC) are two
important phospholipids that show different effects on
lipid metabolism in humans and rodents. Lower PC/PE
ratio induces steatosis or even steatohepatitis in humans[29], however, PE has a greater effect than PC in redu-
cing the cholesterol level in rodents [30]. Our data
showed that RA induced the gene expression of ptdss1
(phosphatidylserine synthase 1), which converts PC to
PE. Consistently, the ptdss1 gene expression is reduced
due to hepatic RXRα deficiency. These gene expression
levels and DNA binding data not only showed the under-
lying mechanism for RA in regulating liver gene expres-
sion, but also suggested the biochemical outcome.Conclusions
Taken together, the differentiation and morphogenetic
effect of RA is well known. However, the current study
provides a comprehensive analysis of the role of RA in
lipid homeostasis. All-trans RA is the most abundant
retinoid that can be easily detected in the liver. Thus,
RA is likely to act as a regulator to control hepatic lipid
metabolism. Since the effect of RA is broad, it is import-
ant to develop specific retinoids in order to target spe-
cific pathways. Such efforts may allow us to identify
compounds that can be used to treat or prevent meta-
bolic syndromes and other lipid-related health issues.Methods
Materials and animal models
Male wild type mice (12 weeks old) and hepatocyte
RXRα-deficient mice (KO) [10,11], which have the same
genetic background of C57BL/6, were used. The RXRα
KO mice were produced and characterized previously
[10,11]. The LoxP sites were inserted into introns flanking
the fourth exon of the RXRα gene covering the DNA
binding domain, which is deleted after crossing the floxed
RXRα allele against a transgenic line in which cre recom-
binase is expressed under the control of the albumin pro-
moter. The mutant mice express a truncated protein that
has the intact ligand binding domain, but lacks the DNA
binding domain. Animal protocols and procedures were
approved by the Institutional Animal Care and Use Com-
mittee (IACUC) at the University of Kansas Medical Cen-
ter and the University of California, Davis.
All ChIP-grade antibodies except anti-RNA Pol II
(Millipore, MA) were purchased from Santa Cruz Biotech-
nology, Inc. (Santa Cruz, CA). DNA purification kit was
purchased from Qiagen Co. (Valencia, CA). All other ChIP-
related reagents were obtained from Invitrogen Co. (Carls-
bad, CA).Animal treatment
Retinoic acid (Sigma-Aldrich, MO) was given to wild
type and hepatic RXRα-deficient mice at a dosage of
150 mg/kg diet for 7 days. As controls, mice were fed
with normal diet.
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ChIP was performed according to our previously pub-
lished study [31]. After fixation, the mouse livers were
subjected to lysis with cell and nuclear lysis buffer. Sonic-
ation was used to fragment the chromatin, followed by
precipitation with specified antibodies. The target DNA
fragments were obtained by reverse crosslinking and puri-
fication. Antibodies against IgG and RNA Pol II were used
as negative and positive controls, respectively.
DNA library preparation and sequencing
By using the End-It DNA End Repair Kit (Illumina,
Madison, WI), DNA fragments prepared from ChIP
were ligated with specified adaptors and amplified, then
size-selected (175-225 bp) on an agarose gel followed by
sequencing (High-Seq 2000, Illumina, Madison, WI).
Alignment, call peak, and annotation of ChIP-seq data
The target sequences were aligned to the mouse genome
(http://hgdownload.cse.ucsc.edu/goldenPath/mm10/bigZips/)
by Bowtie 0.12.7 [32] followed by peak-calling using MACS
(version 1.4.1) [33]. The peaks were annotated using the
database (NCBI37/mm9) by Peak Analyzer [34]. The back-
ground cut off standard was set to be 20 fold of the input sig-
nals [18]. The cut off distance from the transcription start
site (TSS) was set to be 10 kb. Co-localization is defined as
having at least 25% overlap in their peak widths.
Microarray
Affymetrix 430 A_2 Chip (Santa Clara, CA) was used to
determine the genome-wide mRNA expression levels.
Microarray data were annotated using Affymetrix Expres-
sion Console (MAS5). The probe signal with p values less
than 0.05 were used for further analysis.
ChIP-seq data analysis
All data were treated with the same cut off criteria. The
generated RXRα binding data were compared with the data
for RARα, PXR, LXR, FXR, and PPARα. The principle
component analysis (PCA) and cluster analysis package in
SPSS program was used to analyze the global binding data.
For both PCA and cluster analysis, called peaks were
assigned the value of 1. Not called peaks were assigned the
value of 0. Genes with overlapping binding sites of RXRα
and each of RARα, PXR, LXR, FXR, and PPARα at the
same location were functionally analyzed by the DAVID
(http://david.abcc.ncifcrf.gov/) [35].
Lipid homeostasis analysis based on mRNA expression
Genes (579) involved in regulating lipid homeostasis were
extracted from the KEGG database (Kyoto Encyclopedia of
Genes and Genomes, http://www.genome.jp/kegg/). The
expression of those 579 genes were determined in wild
type and liver RXRα KO mice treated with and withoutRA (n = 3) for 7 days. After multiple comparisons, only 30
and 36 out of all 579 lipid homeostasis genes showed sig-
nificant change at the corrected p-value of 0.05 after RA
treatment and RXRα knockout, respectively. Therefore,
IBM SPSS PCA package was used to differentiate groups
based on the global expression pattern of all 579 lipid
homeostasis genes.
Serum lipid assays
Triglyceride, cholesterol, and bile acids in the serum were
assayed using a commercially available kit (Pointe Detroit,
Michigan) that was modified to a 96-well format. Spectro-
photometric analysis was conducted with a Bio-Tek mi-
crotiter plate reader (Bio-Tek, VT).
Availability of supporting data
The microarray and ChIP-Seq data supporting the re-
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